Our Technology for Coronavirus

ENOB-CV-01: Aerosol/Inhaled Treatment Potentially for All Coronaviruses that Cause Human Disease


Hijack RNA Platform
Pre-IND Submission Expected in Near-term
Advanced Pre-clinical

The technology tricks – or Hijacks – the polymerase of Coronaviruses to trigger infected cells to commit suicide instead of becoming virus-producing factories. The code recognized by the Hijack RNA is similar in SARS-CoV-1 and all variants of SARS-CoV-2 (that cause COVID-19) as well as those known to cause 20 percent of common colds.

Dr. Gumrukçu, co-founder and inventor of Enochian BioSciences, and Director of Seraph Research Institute, presented the initial findings at the prestigious Conference on Retroviruses and Opportunistic infections in March 2021 (Slide Presentation Here).

Modeled on the approach taken by operation Warp Speed, production, distribution, and reimbursement potential partners have been identified.

Based on promising experiments in mice, a Pre-IND application is expected in the near term.

ENOB-CV-11: Aerosol/Inhaled Prophylaxis Potentially for All Coronaviruses that Cause Human Disease


Hijack RNA Platform
Pre-IND Submission Expected in Near-term
Advanced Pre-Clinical

The technology is delivered by an AAV particle or nanoparticle, allowing it to wait in ambush for a cell to become infected or until the cells die due to natural turnover. Because target cells of the Coronavirus – respiratory epithelial cells – live up to 6 to 20 months in human airways, it is possible that a single inhalation could protect against infection for relatively long periods of time.

The code recognized by the Hijack RNA is similar in SARS-CoV-1 and all variants of SARS-CoV-2 (that cause COVID-19) as well as those known to cause 20 percent of common colds. Therefore, a single inhaled dose every 6 to 20 months could potentially prevent all variants of Coronaviruses.

Based on promising experiments in mice, a Pre-IND application is expected in the near term.